search
The evolution of targeted therapies has positioned antibody-drug conjugates (ADCs) among the most promising modalities in modern oncology. By combining the targeting precision of biologics with the cell-killing power of cytotoxic drugs, ADCs offer a more focused approach to cancer treatment.
May 12, 2026
In pharmaceutical development, confidence in data is everything. Whether supporting early-stage research or regulatory submissions, analytical methods must consistently deliver accurate and reproducible results. That's where method validation parameters come into play.
May 06, 2026
Antibody-drug conjugates (ADCs) have rapidly become a cornerstone of modern oncology, driven by significant advances in payload-linker technologies. While early ADC programs struggled with stability and manufacturing complexity, recent innovation has drastically improved their clinical viability.
Apr 02, 2026
The development of a new therapy involves multiple stages, from discovery through commercialization. At the center of this process is drug substance manufacturing, where the active pharmaceutical ingredient (API) is produced and refined. Since this stage determines the quality, purity, and scalability of the final therapy, selecting the right development partner can significantly influence project success.
Apr 02, 2026
Low aqueous solubility remains one of the most persistent obstacles in modern drug development programs. Industry studies estimate that roughly 40% of approved drugs and up to 90% of pipeline candidates exhibit poor water solubility. For many compounds, improving solubility is essential to achieving adequate bioavailability and enabling successful clinical and commercial development.
Mar 30, 2026
